These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8652397)

  • 1. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus.
    Ahmad F; Solymoss S; Poon MC; Berube C; Sullivan AK
    Br J Haematol; 1996 Jun; 93(3):700-3. PubMed ID: 8652397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia.
    Krumdieck R; Shaw DR; Huang ST; Poon MC; Rustagi PK
    Am J Med; 1991 May; 90(5):639-45. PubMed ID: 1903026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide.
    Nakamura S; Kato A; Sakata Y; Aoki N
    Br J Haematol; 1988 Mar; 68(3):313-9. PubMed ID: 3258529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The subunit composition of factor XIII proteins in normal and factor XIII deficient plasma and serum analysed by line immunoelectrophoresis.
    Krøll J
    Clin Chim Acta; 1989 Feb; 179(3):279-84. PubMed ID: 2714001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA.
    Fukue H; Anderson K; McPhedran P; Clyne L; McDonagh J
    Blood; 1992 Jan; 79(1):65-74. PubMed ID: 1370210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency.
    Ishida F; Okubo K; Ito T; Okumura N; Souri M; Ichinose A
    Thromb Haemost; 2010 Dec; 104(6):1284-5. PubMed ID: 20941461
    [No Abstract]   [Full Text] [Related]  

  • 7. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.
    Milner GR; Holt PJ; Bottomley J; Maciver JE
    J Clin Pathol; 1977 Aug; 30(8):770-3. PubMed ID: 599192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII.
    Lorand L; Velasco PT; Hill JM; Hoffmeister KJ; Kaye FJ
    Thromb Haemost; 2002 Dec; 88(6):919-23. PubMed ID: 12529739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case with SLE showing acquired low plasma F.XIII level followed by severe hematoma characteristic of F.XIII deficiency].
    Okubo S; Yamano M; Yasunaga K
    Rinsho Ketsueki; 1988 Sep; 29(9):1522-6. PubMed ID: 3216525
    [No Abstract]   [Full Text] [Related]  

  • 10. Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate.
    Daly HM; Carson PJ; Smith JK
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):507-14. PubMed ID: 1768763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations.
    Otis PT; Feinstein DI; Rapaport SI; Patch MJ
    Blood; 1974 Dec; 44(6):771-81. PubMed ID: 4214572
    [No Abstract]   [Full Text] [Related]  

  • 12. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin cross-linking.
    Fear JD; Miloszewski KJ; Losowsky MS
    Acta Haematol; 1984; 71(5):304-9. PubMed ID: 6429995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Factor XIII.
    Muszbek L; Katona É; Kerényi A
    Methods Mol Biol; 2017; 1646():277-293. PubMed ID: 28804836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
    Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
    Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.
    Duncan EM; Dale BJ; Lloyd JV
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):340-8. PubMed ID: 24440916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperviscosity syndrome in a patient with systemic lupus erythematosus.
    Fukasawa T; Arai T; Naruse T; Maekawa T
    Am J Med Sci; 1977; 273(3):329-34. PubMed ID: 868920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A familial factor XIII subunit B deficiency.
    Saito M; Asakura H; Yoshida T; Ito K; Okafuji K; Yoshida T; Matsuda T
    Br J Haematol; 1990 Mar; 74(3):290-4. PubMed ID: 2334637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure.
    Rabik CA; Atkinson MA; Sule S; Strouse JJ
    Transfusion; 2017 Sep; 57(9):2159-2163. PubMed ID: 28707410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency.
    Seiving B; Henriksson P; Stenberg P; Nilsson IM
    Br J Haematol; 1992 Oct; 82(2):414-6. PubMed ID: 1419823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Airway Compromise and Perioperative Management of a Patient with Acquired Factor XIII Inhibitor.
    Tone K; Lalu M; Kilty SJ; Rosenberg E; Tinmouth A
    A A Case Rep; 2015 May; 4(9):120-4. PubMed ID: 25909777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.